133 related articles for article (PubMed ID: 22684727)
1. Extreme value modelling of laboratory safety data from clinical studies.
Southworth H; Heffernan JE
Pharm Stat; 2012; 11(5):361-6. PubMed ID: 22684727
[TBL] [Abstract][Full Text] [Related]
2. Multivariate extreme value modelling of laboratory safety data from clinical studies.
Southworth H; Heffernan JE
Pharm Stat; 2012; 11(5):367-72. PubMed ID: 22888093
[TBL] [Abstract][Full Text] [Related]
3. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
Xia HA; Ma H; Carlin BP
J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
[TBL] [Abstract][Full Text] [Related]
4. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
Wang M; Day R
J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
[TBL] [Abstract][Full Text] [Related]
6. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
Holt MM; Stamey JD; Seaman JW; Young DM
J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of a bayesian method of dose escalation based on bivariate binary responses.
Whitehead J; Zhou Y; Stevens J; Blakey G
J Biopharm Stat; 2004 Nov; 14(4):969-83. PubMed ID: 15587975
[TBL] [Abstract][Full Text] [Related]
8. Bayesian sample size determination for a clinical trial with correlated continuous and binary outcomes.
Stamey JD; Natanegara F; Seaman JW
J Biopharm Stat; 2013; 23(4):790-803. PubMed ID: 23786161
[TBL] [Abstract][Full Text] [Related]
9. Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison models.
Fu H; Price KL; Nilsson ME; Ruberg SJ
J Biopharm Stat; 2013; 23(1):26-42. PubMed ID: 23331219
[TBL] [Abstract][Full Text] [Related]
10. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
11. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
Daimon T
Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
[TBL] [Abstract][Full Text] [Related]
12. Assessing dose-region profile of drug efficacy: a multiregional trial strategy.
Chen YH; Wang M
J Biopharm Stat; 2012 Sep; 22(5):894-902. PubMed ID: 22946938
[TBL] [Abstract][Full Text] [Related]
13. Bayesian population approaches to the analysis of dose escalation studies.
Russu A; De Nicolao G; Poggesi I; Neve M; Gomeni R
Comput Methods Programs Biomed; 2012 Aug; 107(2):189-201. PubMed ID: 21764475
[TBL] [Abstract][Full Text] [Related]
14. Dose finding - a challenge in statistics.
Bretz F; Hsu J; Pinheiro J; Liu Y
Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
[TBL] [Abstract][Full Text] [Related]
15. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
Kikuchi T; Gittins J
Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
[TBL] [Abstract][Full Text] [Related]
16. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
Li W; Fu H
J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
[TBL] [Abstract][Full Text] [Related]
17. BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trials.
Scott JA; Hand AL; Sian LS
J Biopharm Stat; 2011 Sep; 21(5):1030-41. PubMed ID: 21830929
[TBL] [Abstract][Full Text] [Related]
18. Priorities in the benefit-risk assessment of new drugs.
Venning GR
Adverse Drug React Acute Poisoning Rev; 1984; 3(2):113-21. PubMed ID: 6543414
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
Pinheiro J
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
[No Abstract] [Full Text] [Related]
20. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
